Mast Therapeutics Inc (NYSE:MSTX) was the recipient of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 7,102,740 shares, a growth of 12.9% from the October 31st total of 6,290,337 shares. Based on an average daily trading volume, of 4,295,436 shares, the short-interest ratio is currently 1.7 days. Currently, 3.4% of the company’s stock are short sold.

Shares of Mast Therapeutics (NYSE:MSTX) opened at 0.0929 on Wednesday. The stock has a 50 day moving average of $0.08 and a 200 day moving average of $0.31. Mast Therapeutics has a 1-year low of $0.07 and a 1-year high of $0.71. The firm’s market cap is $22.13 million.

Mast Therapeutics (NYSE:MSTX) last posted its earnings results on Tuesday, November 8th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. Equities research analysts anticipate that Mast Therapeutics will post ($0.19) earnings per share for the current fiscal year.

A number of research firms recently commented on MSTX. Laidlaw downgraded shares of Mast Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 21st. Maxim Group set a $5.00 target price on shares of Mast Therapeutics and gave the company a “buy” rating in a research report on Thursday, September 8th. Zacks Investment Research cut shares of Mast Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 12th. Cowen and Company cut shares of Mast Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Friday, September 23rd. Finally, S&P Equity Research increased their price target on shares of Mast Therapeutics from $0.08 to $0.09 in a research note on Friday, October 14th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Mast Therapeutics currently has an average rating of “Hold” and a consensus target price of $2.07.

COPYRIGHT VIOLATION WARNING: “Mast Therapeutics Inc (MSTX) Short Interest Update” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. and international copyright laws. The original version of this report can be viewed at http://www.dailypolitical.com/2016/11/29/mast-therapeutics-inc-mstx-short-interest-update.html.

Mast Therapeutics Company Profile

Mast Therapeutics, Inc is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options.

5 Day Chart for NYSE:MSTX

Receive News & Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.